Search results

9 items matching your search terms.
Filter the results.
Item type













New items since



Sort by relevance · date (newest first) · alphabetically
Located in Newsroom
Located in Newsroom / UNC Lineberger in the News
Clinical Research Forum selects genomic analysis as top 10 research achievement
A cancer genomics study led by UNC Lineberger researchers and other scientists involved in The Cancer Genome Atlas (TCGA) project, a National Cancer Institute and National Human Genome Research Institute-backed effort to create a comprehensive atlas of the genetic changes in cancer, was selected as one of the top 10 clinical research achievements of the year. The project characterized molecular changes in 12 different cancers and revealed a new approach to classifying cancers.
Located in News
Located in Newsroom
New UNC Lineberger faculty recruited to launch T-cell cancer therapy trials
Two new faculty members have joined the UNC Lineberger Comprehensive Cancer Center to help launch groundbreaking immunotherapy clinical trials that will test an experimental treatment in which patients’ own immune cells are genetically engineered to fight their cancer.
Located in News
Located in Newsroom / UNC Lineberger in the News
UNC Lineberger members to share research, expertise at 2015 AACR meeting
UNC Lineberger Comprehensive Cancer Center researchers will share their study findings and expertise at the American Association for Cancer Research’s annual meeting, which is expected to draw thousands to Philadelphia April 18-22 to discuss advances in cancer science.
Located in News
Cancer genetics the focus of UNC Lineberger symposium
UNC Lineberger's 39th annual scientific symposium was held April 8-9 at the William and Ida Friday Center for Continuing Education in Chapel Hill.
Located in News
Study sheds light on why some breast cancers have limited response to immunotherapy
Jonathan Serody, MD, Benjamin Vincent, MD, and a team of UNC Lineberger investigators published findings in the Journal of Clinical Investigation that may explain why drugs designed to unleash the immune system against cancer were ineffective in treating a type of triple negative breast cancer. They determined “claudin-low” tumors were releasing a chemical signal to attract regulatory T-cells, which prevented the immune system from rejecting the cancer.
Located in News